Literature DB >> 12930318

Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma.

Hannes Kaufmann1, Elisabeth Krömer, Thomas Nösslinger, Ansgar Weltermann, Jutta Ackermann, Regina Reisner, Marianne Bernhart, Johannes Drach.   

Abstract

OBJECTIVES: Deletion of chromosome 13q [del(13q)] has emerged as a major adverse prognostic factor in multiple myeloma (MM). Del(13q) is detected two to three times more frequently by interphase fluorescence in situ hybridization (FISH) than by metaphase cytogenetics (CG). However, it has remained unclear whether or not del(13q) detected by FISH only provides the same prognostic information as its detection by CG.
METHODS: We investigated the outcome of 118 consecutive patients with newly diagnosed MM who were studied by both CG and FISH (RB-1 and/or D13S319 probes).
RESULTS: CG revealed informative MM karyotypes in 35 patients (29.7%), with monosomy 13/del(13q) in 16 of them. FISH was indicative for a del(13q) in 43 patients (36.4%). A del(13q) by FISH was present in all 16 patients with monosomy 13/del(13q) by CG and also in four of 19 patients with informative karyotypes and diploid chromosome 13. Furthermore, del(13q) was present by FISH in 23 of 84 patients with diploid/non-informative metaphases by CG. Overall survival of patients with monosomy 13/del(13q) by CG and of patients with del(13q) by FISH only was not significantly different (median, 35.2 months vs. 33.2 months, P = 0.58). In contrast, patients with diploid chromosome 13 by either technique experienced prolonged survival (median, 65.6 months). Presence of abnormal karyotypes was significantly associated with an increased Ki67 growth fraction.
CONCLUSION: FISH of chromosome 13q adds prognostic information to that provided by CG. It is suggested to use FISH analysis in clinical trials if risk stratifications take into consideration the chromosome 13q status.

Entities:  

Mesh:

Year:  2003        PMID: 12930318     DOI: 10.1034/j.1600-0609.2003.00111.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  7 in total

1.  Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases.

Authors:  Cigdem Aydin; Turgay Ulas; Ceren Hangul; Orhan Kemal Yucel; Utku Iltar; Ozan Salim; Deniz Ekinci; Sibel Berker Karauzum
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-25       Impact factor: 0.900

2.  Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.

Authors:  Adrian A Carballo-Zarate; L Jeffrey Medeiros; Lianghua Fang; Jatin J Shah; Donna M Weber; Sheeba K Thomas; Elisabet E Manasanch; Suyang Hao; Qi Shen; Robert Z Orlowski; Pei Lin; Xinyan Lu
Journal:  Mod Pathol       Date:  2017-03-10       Impact factor: 7.842

3.  Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma.

Authors:  Gordon W Dewald; Terry Therneau; Dirk Larson; You Kyoung Lee; Stephanie Fink; Stephanie Smoley; Sarah Paternoster; Adewale Adeyinka; Rhett Ketterling; Daniel L Van Dyke; Rafael Fonseca; Robert Kyle
Journal:  Blood       Date:  2005-07-19       Impact factor: 22.113

4.  An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961.

Authors:  Marilu Nelson; Sherrie L Perkins; Bhavana J Dave; Peter F Coccia; Julia A Bridge; Elizabeth R Lyden; Nyla A Heerema; Mark A Lones; Lauren Harrison; Mitchell S Cairo; Warren G Sanger
Journal:  Br J Haematol       Date:  2009-11-04       Impact factor: 6.998

5.  Evaluation of 13q14 status in multiple myeloma by digital single nucleotide polymorphism technology.

Authors:  Katy Hanlon; Lorna W Harries; Sian Ellard; Claudius E Rudin
Journal:  J Mol Diagn       Date:  2009-07-30       Impact factor: 5.568

Review 6.  The Evolution of Prognostic Factors in Multiple Myeloma.

Authors:  Amr Hanbali; Mona Hassanein; Walid Rasheed; Mahmoud Aljurf; Fahad Alsharif
Journal:  Adv Hematol       Date:  2017-02-21

7.  Conventional and molecular cytogenetic analyses in Turkish patients with multiple myeloma.

Authors:  Beyhan Aras Durak; Olga Meltem Akay; Gülçin Sungar; Güney Bademci; Vahap Aslan; Jülide Caferler; Muhsin Ozdemir; Oğuz Cilingir; Sevilhan Artan; Zafer Gülbaş
Journal:  Turk J Haematol       Date:  2012-06-15       Impact factor: 1.831

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.